Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market

Angelini Pharma S.p.A., the pharmaceutical arm of Italy’s Angelini Industries Group, has agreed to acquire Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) for $31.50 per share in cash, valuing the Coral Gables-based rare disease company at approximately $4.1 billion, or about €3.5 billion. The boards of both companies have unanimously approved the transaction, which marks Angelini Pharma’s first direct entry into the United States market and its largest single deal in a 100-year corporate history. Catalyst Pharmaceuticals shares closed at $31.10 on the Nasdaq on May 7, 2026, leaving the announced takeout price at a 1.3% premium to the last closing price and a 28% premium to the 30-day volume-weighted average through April 22, 2026, the day before reports of the talks first surfaced. Closing is expected in the third quarter of 2026, subject to Catalyst Pharmaceuticals stockholder approval and customary regulatory clearances, with Blackstone funds and select international partners participating in the equity structure and BNP Paribas underwriting the debt package as Sole Global Coordinator.

What does the Angelini Pharma acquisition of Catalyst Pharmaceuticals reveal about the next consolidation wave in US rare disease assets?

The deal is structured to deliver immediate certainty rather than negotiated upside. The 28% premium to the unaffected 30-day volume-weighted average price tells the more honest story of where Catalyst Pharmaceuticals was trading before the acquisition rumour cycle began. Once Bloomberg-style leaks pulled the stock toward the eventual offer price, the headline premium compressed sharply, which is why the May 7 close of $31.10 sits only forty cents below the $31.50 cash consideration. For arbitrage desks, the implied annualised spread on a third-quarter close is thin but clean, reflecting low antitrust risk in a transaction where a European acquirer with no overlapping US commercial footprint is taking out a single-country, three-product rare disease company.

The strategic logic for Angelini Pharma is more interesting than the financial mechanics. Catalyst Pharmaceuticals delivered $589 million in 2025 revenue at 19.8% year-over-year growth and $214.33 million in earnings, up 30.78%, on the back of FIRDAPSE for Lambert-Eaton myasthenic syndrome, AGAMREE for Duchenne muscular dystrophy, and FYCOMPA for partial-onset and primary generalised tonic-clonic seizures. Angelini Pharma is buying a profitable, cash-generative US commercial platform with three approved products, an installed sales infrastructure addressing rare neurological and neuromuscular populations, and clinical specialty access that would take a European mid-cap pharmaceutical company a decade to build organically. The competitive read across to Harmony Biosciences, Amneal Pharmaceuticals, and Supernus Pharmaceuticals is that profitable, single-country rare disease commercial assets in the US are becoming acquisition currency for European groups locked out of scale by domestic market fragmentation.

How does the $4.1 billion Catalyst Pharmaceuticals takeout price compare with the company’s 2025 earnings and growth trajectory?

On a backward-looking basis, the $4.1 billion equity value implies roughly 7 times 2025 revenue and approximately 19 times 2025 earnings, which by US specialty pharma standards is full but not aggressive. The harder valuation question is how Angelini Pharma is underwriting the FIRDAPSE patent cliff. Catalyst Pharmaceuticals settled separate litigation in 2025 with Lupin Pharmaceuticals, granting a generic FIRDAPSE entry in February 2035, and on May 7 announced a parallel settlement with Hetero USA, Inc. that resolves all pending FIRDAPSE patent litigation in the US District Court for the District of New Jersey. The two settlements together remove the single largest legal overhang on Catalyst Pharmaceuticals’s flagship asset and effectively lock in a decade of orphan exclusivity runway for FIRDAPSE inside the deal model.

This sequencing matters because it suggests Angelini Pharma was unwilling to close a $4.1 billion transaction with open generic litigation hanging over the lead asset. The settlement timing, announced concurrently with the merger agreement, indicates Catalyst Pharmaceuticals’s licensor SERB S.A. and the deal team coordinated the resolution as a closing condition in substance even if not in form. From a capital allocation perspective, Angelini Pharma is paying a full multiple but for an asset where the generic exposure has been explicitly bounded to 2035 across all known challengers. That is materially de-risked compared to the typical specialty pharma takeout where buyers inherit unsettled paragraph IV litigation as part of the package.

Why is Blackstone Life Sciences participating in the Angelini Pharma financing structure for the Catalyst Pharmaceuticals acquisition?

The participation of Blackstone funds in the equity financing is the most strategically revealing element of the transaction structure beyond the price itself. Angelini Pharma already has a working relationship with Blackstone Life Sciences through GRIN Therapeutics, the central nervous system asset Angelini Pharma acquired access to in 2024. By bringing Blackstone funds into the Catalyst Pharmaceuticals equity stack alongside select international partners, Angelini Pharma signals two things: first, the deal is too large to absorb on the family-controlled Angelini Industries balance sheet without diluting the broader group’s industrial strategy across healthcare, industrial technology, and consumer goods; second, Blackstone’s continued involvement lends institutional discipline to the integration thesis, particularly on US commercial governance.

BNP Paribas’s role as Sole Global Coordinator and Underwriter on the debt package, with Centerview Partners as lead financial advisor and Morgan Stanley as co-advisor, is an unusually concentrated mandate for a transaction of this size. The single-underwriter structure suggests Angelini Pharma negotiated a fully committed financing package upfront rather than syndicating broadly, which removes financing risk from the announcement but concentrates execution exposure on BNP Paribas. For comparison, recent European pharmaceutical takeouts of US targets have typically used three-bank or four-bank coordinator structures. The streamlined approach here is consistent with a sponsor-style execution playbook, which again points to Blackstone’s influence in shaping the financing architecture.

What does the Catalyst Pharmaceuticals deal mean for the US rare disease competitive landscape and Harmony Biosciences in particular?

Harmony Biosciences is the most direct read-across name. Harmony Biosciences, like Catalyst Pharmaceuticals, runs a focused US rare neurological franchise with a small commercial team, high gross margins, and a single-asset dependency that the market has historically discounted. With Catalyst Pharmaceuticals taken out at 7 times sales, the implied floor for Harmony Biosciences in any future strategic process is now visible to every European mid-cap pharmaceutical company looking for a US commercial beachhead. Supernus Pharmaceuticals and Amneal Pharmaceuticals fall into a similar reference set, although both carry more diversified portfolios that complicate clean comparability.

The second-order effect is on rare disease licensing economics. Catalyst Pharmaceuticals’s growth playbook was built on disciplined in-licensing, including the FYCOMPA US rights acquired from Eisai in 2023 and the AGAMREE rights for Duchenne muscular dystrophy. By absorbing Catalyst Pharmaceuticals, Angelini Pharma inherits not just the products but the deal-making relationships that produced them. European biotech companies and Japanese pharmaceutical groups that previously viewed Catalyst Pharmaceuticals as a preferred US commercial partner will now negotiate with a different counterparty under Italian ownership, which may shift licensing economics toward larger upfronts and tighter milestone definitions as Angelini Pharma builds out its US commercial bandwidth.

What execution risks could derail the Angelini Pharma integration of Catalyst Pharmaceuticals between signing and 2027?

Three execution risks dominate. The first is regulatory. The Federal Trade Commission and the Department of Justice will receive the FIRDAPSE patent settlement with Hetero USA, Inc. for review under the standard reverse-payment scrutiny framework that has tightened materially since 2023. While the settlement itself does not appear to involve a reverse payment in the classical sense, the FTC has signalled it will examine all generic settlement agreements involving rare disease drugs more closely, and any objection could delay the third-quarter 2026 close even if it does not ultimately block the underlying transaction.

The second risk is commercial integration. Angelini Pharma operates directly in 20 countries with more than 3,000 employees but has no current US commercial footprint of scale. Importing Italian governance into a US specialty pharma sales organisation is a recurring failure mode in trans-Atlantic pharmaceutical deals, particularly where the acquired commercial team has built incentive structures and physician relationships independently. The Catalyst Pharmaceuticals senior commercial team’s retention through closing and into 2027 will be the single most important leading indicator of whether the integration thesis holds.

The third risk is portfolio cannibalisation between Ontozry, Angelini Pharma’s existing epilepsy asset, and FYCOMPA, which Catalyst Pharmaceuticals acquired from Eisai in 2023. Both products address focal-onset seizure populations with overlapping prescriber bases. Angelini Pharma will need to articulate a coherent positioning strategy between the two assets within the first year post-close, or risk channel confusion that erodes the prescription momentum FYCOMPA has built since the Eisai transition.

How does the Catalyst Pharmaceuticals transaction reposition Angelini Pharma against European specialty pharmaceutical peers?

For Angelini Pharma, the deal closes the strategic gap with European specialty pharmaceutical peers like Lundbeck, UCB, and Recordati that have either built or acquired US commercial platforms over the last decade. Angelini Pharma’s century-long Italian heritage, family chairmanship under Thea Paola Angelini, and commercial focus on Brain Health and consumer health products had until now constrained it to a European and emerging-market footprint. Catalyst Pharmaceuticals delivers the missing US revenue base in a single transaction, taking pro-forma group revenue meaningfully above €2 billion and shifting the geographic mix toward the highest-margin pharmaceutical market in the world.

The financial market signal is equally important. Angelini Industries is privately held, but the willingness of Blackstone funds to anchor the equity financing and BNP Paribas to underwrite the debt independently validates Angelini Pharma as institutional-grade credit and capable of supporting further bolt-on acquisitions in US rare disease. The transformation from a family-controlled Italian consumer health and pharmaceuticals group to a transatlantic Brain Health and rare disease platform is the underlying thesis, and the Catalyst Pharmaceuticals acquisition is the foundational transaction that makes that thesis credible to capital markets.

Key takeaways on what the Angelini Pharma acquisition of Catalyst Pharmaceuticals means for the company, its competitors, and the industry

• Angelini Pharma is paying $4.1 billion in cash at $31.50 per Catalyst Pharmaceuticals share, a 28% premium to the 30-day volume-weighted average through April 22, 2026, but only 1.3% above the May 7, 2026 close of $31.10, meaning the market had already priced in most of the takeout
• The deal gives Angelini Pharma immediate US commercial scale through FIRDAPSE, AGAMREE, and FYCOMPA, three approved products in rare neuromuscular and neurological indications with $589 million in combined 2025 revenue
• Catalyst Pharmaceuticals’s concurrent FIRDAPSE patent settlement with Hetero USA, Inc., following the 2025 Lupin Pharmaceuticals settlement, locks in generic exclusivity to February 2035 and removes the single largest legal overhang from the deal model
• Blackstone funds participating in the equity financing extend an existing Angelini Pharma relationship through GRIN Therapeutics and bring sponsor-style discipline to US commercial governance post-close
• BNP Paribas as Sole Global Coordinator and Underwriter on the debt package signals a fully committed financing structure with no syndication risk at announcement, an unusually concentrated mandate for a $4.1 billion transaction
• Harmony Biosciences becomes the most directly comparable read-across name in US rare neurological assets, with Catalyst Pharmaceuticals’s takeout multiple of approximately 7 times sales setting a visible floor for similar single-country commercial platforms
• The FTC and Department of Justice review of the FIRDAPSE Hetero settlement is the primary regulatory wildcard, although the agreement does not appear to involve a classical reverse payment structure
• Portfolio overlap between Angelini Pharma’s existing epilepsy asset Ontozry and Catalyst Pharmaceuticals’s FYCOMPA is the most under-discussed integration risk and will require explicit positioning within twelve months of close
• Angelini Pharma moves from a European and emerging-markets specialty pharmaceutical company to a transatlantic Brain Health and rare disease platform, closing a strategic gap with peers like Lundbeck, UCB, and Recordati
• For European biotech companies and Japanese pharmaceutical groups that previously viewed Catalyst Pharmaceuticals as a preferred US licensing partner, the change of ownership shifts negotiation dynamics toward larger upfronts and tighter milestone definitions